1-Isopropylpiperazine → HCID 86730056, 화합물
반응식
[C:1](=[O:26])(OC1C=CC([N+]([O-])=O)=CC=1)[O:2][CH:3]1[CH2:6][N:5]([C:7]2[CH:12]=[CH:11][C:10]([C:13](=[O:15])[NH2:14])=[CH:9][N:8]=2)[CH2:4]1.[CH:27]([N:30]1[CH2:35][CH2:34][NH:33][CH2:32][CH2:31]1)([CH3:29])[CH3:28]>C(Cl)Cl>[CH:27]([N:30]1[CH2:35][CH2:34][N:33]([C:1]([O:2][CH:3]2[CH2:4][N:5]([C:7]3[CH:12]=[CH:11][C:10]([C:13](=[O:15])[NH2:14])=[CH:9][N:8]=3)[CH2:6]2)=[O:26])[CH2:32][CH2:31]1)([CH3:29])[CH3:28]참가 물질
4
실험 절차
To a solution of 1-(5-carbamoylpyridin-2-yl)-azetidin-3-yl 4-nitrophenyl carbonate (0.36 g, 1 mmol) in DCM (5 mL) under nitrogen was added 1-isopropylpiperazine (0.13 g, 1 mmol). The resulting solution was stirred under N2 at room temperature for 24 h. The reaction mixture was then filtered and the filter cake was washed with DCM. The combined filtrates were concentrated to afford the crude product. After further purified by preparative HPLC, the title compound (35 mg, 10%) was obtained as a yellow solid. [1HNMR (500 MHz, CDCl3) δ8.58 (d, 1H), 7.96 (dd, 1H), 7.76 (s, 1H), 7.77 (s, 1H), 7.15 (s, 1H), 6.41 (d, 1H), 5.21 (m, 1H), 4.32 (m, 2H), 3.92 (m, 2H), 3.41 (m, 4H), 2.65 (m, 1H), 2.40 (m, 4H), 0.95 (d, 6H); LCMS RtA=1.59 min, [M+H]+=348.2].